$XBI $93.33 | +0.086%
Covid Updates
$
Pipeline Updates
$SPRO -4.1% Spero Therapeutics Tebipenem Pivoxil Hydrobromide Phase 3 Data Published in The New England Journal of Medicine source
$ERYP -1.9% ERYTECH ANNOUNCES PUBLICATION OF POSITIVE RESULTS FROM ERYASPASE PHASE 2 TRIAL IN HYPERSENSITIVE ALL IN THE BRITISH JOURNAL OF HAEMATOLOGY source
$ADVM -1.5% Adverum Biotechnologies Proceeds with IND Amendment for ADVM-022 Phase 2 Trial in Wet AMD After Receiving Requested Type C Meeting Feedback from the FDA source
$AVDL +0.2% Avadel Pharmaceuticals Announces Publication of Positive Secondary Endpoint Data from Pivotal Phase 3 REST-ON Trial. source
$RYTM -16.3% Rhythm Pharmaceuticals Optimizes Design of EMANATE and DAYBREAK Clinical Trials to Advance Setmelanotide for Rare Genetic Diseases of Obesity. source
$ARQT -0.7% Arcutis Completes Enrollment in ARRECTOR Pivotal Phase 3 Trial of Topical Roflumilast Foam in Scalp and Body Psoriasis. source
$TGTX +0.2% TG Therapeutics Announces Oral Presentation of Data from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis at the American Academy of Neurology Annual Meeting. source
$TNXP -2.9% Tonix Pharmaceuticals Announces IND Clearance for TNX-102 SL as a Potential Treatment for Long COVID Syndrome, Also Known as Post-Acute Sequelae of COVID-19 (PASC). source
$SLS -4.1% SELLAS Life Sciences Announces Achievement of Development Milestone for Approval of IND for Galinpepimut-S in China. source
$RVLP +0.6% RVL Pharmaceuticals plc Announces Preliminary First Quarter 2022 UPNEEQ® Net Product Sales Results. source
$CTXR -7.1% Citius Pharmaceuticals Reports Topline Data from the Pivotal Phase 3 Study of Cancer Immunotherapy I/ONTAK (E7777) for the Treatment of Persistent or Recurrent Cutaneous T-Cell Lymphoma (CTCL) in Support of BLA Submission. source
$UTHR +0.4% United Therapeutics Announces the Publication of Tyvaso DPI™ BREEZE Clinical and Long-term Data in the Journal Pulmonary Circulation. source
Business Updates
$VACC +0.4% Vaccitech Announces Notification of Milestone and Royalty Revenue Relating to Sales of Vaxzevria® source
$BHVN +0.8% Biohaven Expands Commitment to Supporting Veterans and Military Through Sole Sponsorship of National Headache Foundation's (NHF) Outreach Program. source
Posted by FS/JM
Comments